Dear , 

Fuel3D is a leading 3D capture and imaging business. Its unique, market-leading technology has a broad range of applications across multiple industry sectors. The Company’s intellectual property allows companies to utilise cost-effective, fast and accurate 3D image capture to improve existing practices, provide enhanced services to customers and gain advantages in their markets.
Fuel3D’s unique technology captures images at a speed faster than a tenth of a second and offers a unique capability for scanning organic subjects and capturing highly accurate data.

The Technology

Fuel3D is the world’s first 3D scanner to combine pre-calibrated stereo cameras with photometric imaging to capture and process a 3D model in seconds. When taking an image, the scanner rapidly acquires a series of stereoscopic 2D photographs with several lighting directions. These are then processed by software to create a single 3D image.
Fuel3D’s scanner combines a number of image processing technologies to allow on-the-spot acquisition of high quality 3D images:

• Photometric imaging is used to acquire colour and high-frequency 3D detail from the subject
• Optical localization is used to determine the position of the imaging device during the acquisition process
• Geometric imaging is used to acquire accurate underlying 3D shape information from the subject
• Data fusion is performed to combine the data output of the photometric and geometric processes to produce a single 3D image

The Market Opportunity

Having spent the last 2 years developing its hardware and software platform, Fuel3D is now focussing its technology on a limited number of vertical markets where it believes the greatest possibilities exist for revenue generating opportunities. The primary focus will be on eyewear, where the company has several ongoing customers trialling the technology, as well as a significant H2020 grant to develop a full-face capture from a single scan to provide data to support the provision of customised eye-ware.

In addition, having spent over a year working with a leading global pharmaceutical player, the company has developed a scanning system complete with a measurement package that will help set new standards for therapeutic assessment in the clinical trial industry. This product ‘BioVolume’ was demonstrated at CES in January 2017.

Further, Fuel3D have signed commercial agreements with two other companies to license and sell products already developed using the company’s technology in foot scanning and brain surgery.

Each of the company’s main verticals is a multi-$bn market with significant addressable markets for Fuel3D. For example, the opportunity for spectacle manufacturers to 3D print glasses frames to fit client’s specifications would reduce cost and time dramatically in this $100bn+ market.

The Team

A new management team has been installed to take the company on the next stage of its journey.

George Thaw, CEO, joined Fuel3D in Q1 2017 with a wealth of technology and management experience. He has held CEO roles at Advanced Health and Care, a division of Advanced Computer Software (ACS) Group (one of the largest suppliers of leading IT solutions in the Health sector) and Powa, the e- and m- commerce market-place. Previously George held COO roles at SAP (UK & Ireland) and Arctic Slope Regional Corp. He spent 9 years at Microsoft in various Business service and development roles.

Mark Jaffray, Interim Chairman, is a serial early-stage technology investor and he sits on the Boards of Rota (an AI based HR platform) and Brainomix (an imaging software company active in neurology).

Mike Johns, CFO, also joined in Q1 2017, and has held CEO and CFO positions at several technology businesses over the years including PowaData, FusePump, TIS Software and Iris Financial Solutions.

This financial promotion is issued by Parkwalk Advisors Limited (Parkwalk), which is authorised and regulated by the Financial Conduct Authority. Investments referred to in this newsletter are not suitable for all investors.  Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any product.  Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Parkwalk is not able to provide advice as to the suitability of investing in any product.